Haploidentical Transplant Achieves Long-Term Remission in Relapsed Refractory Leukemia With Fludarabine-Induced Neurotoxicity Complication

Exp Clin Transplant. 2023 Mar;21(3):279-285. doi: 10.6002/ect.2022.0383.

Abstract

Hematopoietic stem cell transplant is potentially curative for relapsed/refractory leukemia. However, neurotoxicity is common and has been reported in 11% to 59% of children following hematopoietic stem cell transplant. Most pediatric studies of the neurological effects of hematopoietic stem cell transplant have focused on acute neurotoxicity. Limited information is available for long-term neurotoxicity, particularly those cases that are severe and permanent and caused by conditioning chemotherapy. Here, we report 2 cases of relapsed acute lymphoblastic leukemia that achieved long-term remission by haploidentical hematopoietic stem cell transplant but remained complicated with severe and persistent fludarabine-induced neurotoxicity.

Publication types

  • Case Reports

MeSH terms

  • Child
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Transplantation Conditioning
  • Transplants*
  • Vidarabine / adverse effects

Substances

  • fludarabine
  • Vidarabine